Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Medrossiprogesterone acetato - Direct communication with healthcare professionals on Medrossiprogesterone acetato
Direct communication with healthcare professionals on Medrossiprogesterone acetato
Medroxyprogesterone acetate: Risk of meningioma and measures to minimise this risk.
Summary
- There is an increased risk of developing meningioma with high doses of medroxyprogesterone acetate (all injectable and ≥100 mg oral formulations), primarily after prolonged use (several years).
- For contraception or non-oncological indications:
- Medicines containing high doses medroxyprogesterone acetate are contraindicated in patients with meningioma or a history of meningioma.
- If meningioma is diagnosed in a patient treated with high doses medroxyprogesterone acetate, treatment must be stopped.
- For oncological indications:
- If a meningioma is diagnosed in a patient treated with high doses medroxyprogesterone acetate, the need to continue the treatment should be carefully reconsidered, on a case-by-case basis taking into account individual benefits and risks.
- Patients treated with high doses medroxyprogesterone acetate should be monitored for signs and symptoms of meningioma in accordance with clinical practice.
Published on: 10 October 2024
Tumore del pancreas: AIFA già al lavoro sul daraxonrasib per garantire accesso equo e tempestivo.
D...
Vai al post →
📅 18 novembre
Oggi si celebra la Giornata europea degli #antibiotici (European Antibiotic Awareness...
Vai al post →
Una legislazione farmaceutica moderna è fondamentale per accompagnare l'#innovazione e garantire ai ...
Vai al post →
Si conclude la campagna #MedSafetyWeek di quest’anno! 🎉
Grazie per aver seguito i nostri canali in...
Vai al post →
Se sei un professionista sanitario, cogli l’occasione per discutere e individuare gli effetti indesi...
Vai al post →
💬 Ti è mai capitato di pensare “è solo un’eruzione cutanea”, “sono soltanto stressato” o “probabilm...
Vai al post →
